TY - JOUR
T1 - A randomized placebo controlled trial of vitamin E for alcoholic hepatitis
AU - Mezey, Esteban
AU - Potter, James J.
AU - Rennie-Tankersley, Lynda
AU - Caballeria, Juan
AU - Pares, Albert
N1 - Funding Information:
The assistance of Dr Llorenc Caballeria and of Ms Merce Roca in this study is gratefully acknowledged. This study was supported in part by grants from the Comision Interministerial de Ciencia y Tecnologia (CICYT SAF98-009) and the Instituto de Salud Carlos III (V-2003-REDC02).
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2004/1
Y1 - 2004/1
N2 - Background/Aims: The effect of vitamin E administration on clinical and laboratory parameters of liver function and on markers of fibrogenesis was assessed in patients with mild to moderate alcoholic hepatitis in a double blind placebo controlled randomized trial. Methods: Twenty-five patients received 1000 I.U. of vitamin E per day, while 26 patients received placebo for 3 months. The patients were followed for 1 year after entry into the trial. Results: Vitamin E did not result in significant greater decreases in serum aminotransferases and serum bilirubin or in greater increases in serum albumin as compared with placebo. Prothrombin time did not change, while serum creatinine remained in the normal range. Monocyte nuclear nuclear factor-κB binding activity decreased in patients who remained abstinent, regardless of whether they received vitamin E. As regards markers of hepatic fibrogenesis, vitamin E treatment decreased serum hyaluronic acid (P < 0.05) while serum aminoterminal peptide of type III procollagen did not change in either group. Four patients in the treatment group and five in the placebo group died during the 1-year study. Conclusions: Vitamin E treatment improves serum hyaluronic acid but has no beneficial effects on tests of liver function in patients with mild to moderate alcoholic hepatitis.
AB - Background/Aims: The effect of vitamin E administration on clinical and laboratory parameters of liver function and on markers of fibrogenesis was assessed in patients with mild to moderate alcoholic hepatitis in a double blind placebo controlled randomized trial. Methods: Twenty-five patients received 1000 I.U. of vitamin E per day, while 26 patients received placebo for 3 months. The patients were followed for 1 year after entry into the trial. Results: Vitamin E did not result in significant greater decreases in serum aminotransferases and serum bilirubin or in greater increases in serum albumin as compared with placebo. Prothrombin time did not change, while serum creatinine remained in the normal range. Monocyte nuclear nuclear factor-κB binding activity decreased in patients who remained abstinent, regardless of whether they received vitamin E. As regards markers of hepatic fibrogenesis, vitamin E treatment decreased serum hyaluronic acid (P < 0.05) while serum aminoterminal peptide of type III procollagen did not change in either group. Four patients in the treatment group and five in the placebo group died during the 1-year study. Conclusions: Vitamin E treatment improves serum hyaluronic acid but has no beneficial effects on tests of liver function in patients with mild to moderate alcoholic hepatitis.
KW - Aminoterminal peptide of type III procollagen
KW - Hyaluronic acid
KW - Nuclear factor-κB
KW - α-Tocopherol
UR - http://www.scopus.com/inward/record.url?scp=0347950972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0347950972&partnerID=8YFLogxK
U2 - 10.1016/S0168-8278(03)00476-8
DO - 10.1016/S0168-8278(03)00476-8
M3 - Article
C2 - 14672612
AN - SCOPUS:0347950972
SN - 0168-8278
VL - 40
SP - 40
EP - 46
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 1
ER -